Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquisition |
multiple biotech firms
|
| gptkbp:ceo |
gptkb:Dr._J._Michael_Bishop
|
| gptkbp:clinical_trial |
ongoing
|
| gptkbp:employees |
over 100
|
| gptkbp:focus |
cancer therapies
|
| gptkbp:founded |
gptkb:2006
|
| gptkbp:founder |
gptkb:Dr._J._Michael_Bishop
|
| gptkbp:headquarters |
gptkb:Newark,_Delaware
|
| https://www.w3.org/2000/01/rdf-schema#label |
SRNE
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:partnerships |
various pharmaceutical companies
|
| gptkbp:products |
gptkb:Sorrento_Therapeutics
|
| gptkbp:research_areas |
gptkb:immunotherapy
|
| gptkbp:revenue |
varies annually
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:website |
www.sorrentotherapeutics.com
|
| gptkbp:bfsParent |
gptkb:Sorrento_Therapeutics,_Inc.
gptkb:Sorrento_Therapeutics |
| gptkbp:bfsLayer |
6
|